The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Primorus Adds Three Directors To Board

Wed, 23rd Sep 2020 19:22

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Primorus Investments PLC - investment firm focussed on natural resources sector - Appoints Rupert Labrum, Hedley Clark and Matthew Beardmore as directors, subject to due diligence checks, following request from unnamed investor who initially sought to requisition general meeting. Donald Strang to step down when new additions join board but Executive Chair Jeremy Taylor-Firth and Executive Director Alastair Clayton to remain. Primorus notes that notice to requisition general meeting has been withdrawn.

----------

Templeton Emerging Markets IT PLC - emerging markets investor - Adds Medha Samant to board as non-executive director from October 1. Spent about 10 years as investment director for Asian equities at Fidelity International.

----------

Asimilar Group PLC - technology-focused investor - Mark Horrocks joins immediately as non-executive director. "He has worked as a research analyst and fund manager for a FTSE100 insurance group," Asimilar notes. Donald Stewart to step down from board at the conclusion of company annual general meeting.

----------

BB Healthcare Trust PLC - healthcare-focused investor - Appoints Toby Young as non-executive director immediately. "Professor Young is a practicing frontline NHS consultant urological surgeon, director of medical Innovation at Anglia Ruskin University, president of the Institute of Decontamination Sciences, and national clinical director for Innovation for the NHS," BB Healthcare said.

----------

4d Pharma PLC - drug developer - Adds Katrin Rupalla to board as non-executive director with immediate effect. Chief Executive Officer Duncan Peyton said: "We are delighted to be able to attract someone of Katrin's calibre to our board of directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel live biotherapeutics into and through the clinic."

----------

Hurricane Energy PLC - Goldaming, England-based oil exploration company - Non-executive Director Alan Parsley retired with effect Wednesday. Leonard Tao also steps down as alternate.

----------

Base Resources Ltd - Australia-based mineral sands producer and developer - Appoints Janine Herzig to board as non-executive director from October 12. "Ms Herzig has 30 years' experience in the resources sector, encompassing executive management, consulting, technical and production roles, across all commodities including industrial minerals," Base said. Sam Willis to step down as a non-executive director from November 20.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2022 11:07

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed.

Read more
1 Apr 2022 09:56

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
1 Apr 2022 08:11

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded

4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30.3 million the year before.

Read more
23 Mar 2022 11:21

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
23 Mar 2022 11:16

4d Pharma shares jump on positive results from cancer treatment study

(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytruda for the treatment of renal cell carcinoma showed positive results.

Read more
9 Mar 2022 19:26

IN BRIEF: 4D Pharma registers for potential ADS offering in US

4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following which the company may offer up to USD150.0 million of shares in the form of American Depositary Shares, with each ADS reflecting eight ordinary shares.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2022 09:55

4d Pharma gets FDA clearance for potential Parkinson's treatments

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has cleared investigational new drug applications for 'MRx0005' and 'MRx0029', for the treatment of Parkinson's disease.

Read more
27 Jan 2022 13:20

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

Read more
4 Jan 2022 10:32

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

IN BRIEF: 4d Pharma names John Doyle as new chief financial officer

Read more
13 Dec 2021 10:55

4D Pharma announces positive results in asthma treatment trials

4D Pharma announces positive results in asthma treatment trials

Read more
30 Sep 2021 11:05

4D Pharma pretax loss grows in first half after Spac merger costs

4D Pharma pretax loss grows in first half after Spac merger costs

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
26 Jul 2021 16:23

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

EXECUTIVE CHANGES: Persimmon finance boss retires; Block fights Forest

Read more
4 Jun 2021 10:32

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.